Cannabis-based medicinal products : guidance (NG144)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
11 November 2019

Abstract

This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.

NICE has published technology appraisal guidance on cannabidiol with clobazam for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

Recommendations

This guideline includes recommendations on:

Products covered by the guideline include:

  • cannabis-based products for medicinal use as set out by the UK Government in the 2018 Regulations
  • the licensed products delta-9-tetrahydrocannibinol combined with cannabidiol (Sativex) and nabilone
  • plant-derived cannabinoids such as pure cannabidiol (CBD)
  • synthetic compounds which are identical in structure to naturally occurring cannabinoids such as delta-9-tetrahydrocannabinol (THC), for example, dronabinol.

Who is it for?

  • Healthcare professionals
  • People taking cannabis-based medicinal products, their families and carers

Guideline development process

How we develop NICE guidelines